Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience-Reference-Cited by-同舟云学术

Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience

Published:2023-03-26 Issue:1 Volume:10 Page:78-89
ISSN:2410-1893
Container-title:Research and Practical Medicine Journal
language:
Short-container-title:Issled. prakt. med. (Print)

Author:

Berezin P. G.¹^ORCID,Milovanov V. V.¹,Ivannikov A. A.¹,Ognerubov N. A.²^ORCID

Affiliation:

1. Tambov Regional Oncological Clinical Dispensary

2. Tambov Regional Oncological Clinical Dispensary; Derzhavin Tambov State University

Abstract

Purpose of the study. To evaluate the results of first‑line treatment in patients with metastatic castration‑resistant prostate cancer (mCRPC).Patients and methods. The evaluation of own clinical observations of 25 patients with mCRPC for the period from July 2014 to July 2021 by random sampling is given. Patients are divided into the ISUP group, the status of the initial treatment, and the type of previous treatment. Therapy was determined by the nature of progression. The following drugs were used as therapeutic agents: docetaxel, enzalutamide, abiraterone acetate + prednisolone, strontium (89 150 mBq). Results evaluation was carried out by RECIST 1.1. criteria. Statistical data processing was carried out using programs SPSS Statistica 2.0.Results. When assessing the tumor response to the therapy in 2 (8 %) patients, a complete therapeutic response was obtained, partial was registered in 4 (16 %) cases, stabilization in 9 (36 %), progression in 10 (40 %). The main response was stabilization and partial response, which was noted in 13 (52 %) patients. On 11 (44 %) patients with bone metastases as the cause of mCRPC, enzalutamide showed the best effect. Patients with lymph node metastases 3 (12 %) had a partial and complete response with a combined treatment regimen – lymphadenectomy + enzalutamide. In the group of patients n = 9 (36 %) – metastases to lymph nodes and bones, the best effect in the form of stabilization and partial response in enzalutamide. In 1 (4 %) patient with visceral progressing metastatic pleural lesion. Two patients had passed away by the end of the research.Conclusion. Enzalutamide and abiraterone showed the best responses in metastatic bone damage (as the cause of mCRPC). We observed more than 50 % of stabilizations during enzalutamide treatment. Combined treatment regimens should be used among patients with only metastatic lymph node lesion (oligo metastasis): this makes it possible to achieve a complete response and a greater number of stabilizations in some patients.

Publisher

QUASAR, LLC

Subject

Microbiology (medical),Immunology,Immunology and Allergy

Reference26 articles.

1. Kostin AA, Kulchenko NG, Tolkachev AO. Forecasting the development of cancer of prostate. multidisciplinary approach. Bulletin of the Medical Institute “REAVIZ” (Rehabilitation, Doctor and Health). 2017;1(25):60–67. (In Russ.).

2. Kostin AA, Kulchenko NG, Tolkachev AO. Prostate cancer. principles of early diagnosis. RUDN Journal of Medicine. 2016;4:68–76. (In Russ.).

3. The state of oncological care of the Russian population in 2019. Edited by A. D. Kaprin, V. V. Starinsky, A. O. Shakhzadovа. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation; 2020, 236 p. (In Russ.). Available at: https://glavonco.ru/cancer_register/Помощь%202019.pdf. Accessed: 17.02.2023.

4. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Petrova GV. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2020, 252 p. (In Russ.). Available at: https://glavonco.ru/cancer_register/Забол_2019_Электр.pdf. Accessed: 17.02.2023.

5. Prostate cancer. Clinical recommendations. Approved at the meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (protocol from 12/25/2020 № 17‑4/4884). (In Russ.). Available at: https://oncology‑association.ru/wp‑content/uploads/2021/02/rpzh.pdf. Accessed: 17.02.2023.